X

Alpa Laboratories Ltd. Stock Analysis

Small Cap
Evaluated by 480 users | BSE: 532878 | NSE: ALPA |
Pharmaceuticals & Drugs
Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 0.59%0.98%-2.9%-3.62%0.46%7.21%7.19%4.97%2.27%4.57%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 82.955.156.156.757.453.563.462.37886
Y-o-Y Gr. Rt.--33.5%1.8%1.1%1.2%-6.8%18.5%-1.8%25.2%10.2%
Adjusted EPS (Rs.) 0.20.08-2.16-2.61-0.323.523.322.220.982.31
Y-o-Y Gr. Rt.--60%-2800%NANANA-5.7%-33.1%-55.9%135.7%
Book Value per Share (Rs.) 46.2446.544.4241.9741.1444.8246.7949.0750.4452.39
Adjusted Net Profit 0.40.2-4.6-5.5-0.77.474.72.14.9
Net Op. Cash Flow (Rs. Cr.) 4.9-12.68.1-1.8-24.8-8.1-7.3-0.717.7
Debt to Cash Flow from Ops 1.92-11.496.542.85-15.57-0.98-1.32-0.82-2.460.02
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Alpa Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 0.4%8.4%10.7%10.2%
Adjusted EPS 31.2%NA-11.4%135.7%
Book Value per Share 1.453.83.9
Share Price 18.9% 2.8% 8.8% 181.6%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 0.430.17-4.75-6.04-0.778.27.254.641.984.49
Operating Profit Margin (%) 2.094.615.39.994.7611.6811.226.651.626.91
Net Profit Margin (%) 0.50.31-8.1-9.68-1.1713.8611.027.512.655.65
Debt to Equity 0.10.120.180.260.330.260.110.060.020
Working Capital Days 260378322263249403432356280238
Cash Conversion Cycle 89122129138128146147148126106
Entity Percentage Holding
Promoters 56.66%
Non-Institutions 43.34%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Alpa Laboratories Ltd.'s performance infers:

Alpa Laboratories Ltd. earnings have grown by 0%, whereas share price has appreciated 2.8% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Alpa Laboratories Ltd. share prices over the last 10 years. Here is what we found out:

Alpa Laboratories Ltd. share price has appreciated 10% annually over the past ten years.

Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company became a private limited company and a decade later it became a public limited enterprise.

The company manufactures a spectrum of products such as ethical drugs, generic drugs, over the counter

Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company became a private limited company and a decade later it became a public limited enterprise.

The company manufactures a spectrum of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products. These products are manufactured in various dosage forms such as injectables (vials/ampoules both liquid and dry), tablets, capsules, eye/ear drops, ointment and creams. The company markets these products under the trademark 'Alpa'.

The company manufactures formulations for other major pharmaceutical companies namely Cipla, Zydus Cadila, Lupin, Glenmark, Genom, Biotech Jenburkt etc. Alpa Laboratories exports a wide range of products to countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka, etc.

Products

The company manufactures a wide range of drugs and formulation for human use. These drugs cater to therapeutic segments such as antibacterial, anti-inflammatory, anti-allergic, anti-histaminics and anti-infective are among others. It manufactures products such as Alquin, optamycin, Amoxycillin capsules and many more

Alpha Labs also manufactures veterinary products such as diphen and grotax-250 among others.

Milestones

1988- Alpa Laboratories was incorporated as private limited company.

1997- The company set up a manufacturing facility at Pigdamber, Indore.

1998- It was converted into public limited enterprise

1999- The company started of commercial production of the unit.

2001- Alpha received WHO GMP Certification for its manufacturing facilities. It entered into an agreement with Plethico Pharmaceuticals for contract manufacturing. The company’s Pigdamber unit were certified as WHO GMP compliant by SGS-ICS Belgium for the period 2001-02.

2003- The Pigdamber unit received ISO 9001: 2000 certification. The same year company started exporting its veterinary products. It registered 7 veterinary products in Sudan.

2006- The company established veterinary division with a new face and ethical promotion of its veterinary products launched in 5 states. Alpha also launched Ethical division for its human products.

2007- Alpa Laboratories collaborated with Vhermann Pharmaceutical Inc Philippines for distribution of its products international marketing

Future plans

Alpa Laboratories is engaged in developing new products and services to strengthen its presence. The company also plans to explore untapped markets.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback